MX2022003982A - Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. - Google Patents

Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.

Info

Publication number
MX2022003982A
MX2022003982A MX2022003982A MX2022003982A MX2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A MX 2022003982 A MX2022003982 A MX 2022003982A
Authority
MX
Mexico
Prior art keywords
sub
methods
receptor
conditions related
treating conditions
Prior art date
Application number
MX2022003982A
Other languages
English (en)
Spanish (es)
Inventor
Thai Curtis Nguyen-Cleary
Lisette Marie Acevedo
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2022003982A publication Critical patent/MX2022003982A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
MX2022003982A 2019-10-01 2020-09-30 Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1. MX2022003982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
PCT/US2020/053642 WO2021067506A1 (en) 2019-10-01 2020-09-30 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
MX2022003982A true MX2022003982A (es) 2022-07-12

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003982A MX2022003982A (es) 2019-10-01 2020-09-30 Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.

Country Status (12)

Country Link
US (1) US20220347158A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037678A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022550458A (cg-RX-API-DMAC7.html)
KR (1) KR20220074913A (cg-RX-API-DMAC7.html)
CN (2) CN119280227A (cg-RX-API-DMAC7.html)
AU (1) AU2020360413A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005999A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156182A1 (cg-RX-API-DMAC7.html)
IL (1) IL291654A (cg-RX-API-DMAC7.html)
MX (1) MX2022003982A (cg-RX-API-DMAC7.html)
TW (1) TW202114656A (cg-RX-API-DMAC7.html)
WO (1) WO2021067506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023135506A1 (en) 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) * 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) * 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) * 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) * 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법

Also Published As

Publication number Publication date
US20220347158A1 (en) 2022-11-03
KR20220074913A (ko) 2022-06-03
WO2021067506A1 (en) 2021-04-08
JP2022550458A (ja) 2022-12-01
TW202114656A (zh) 2021-04-16
AU2020360413A1 (en) 2022-04-14
CA3156182A1 (en) 2021-04-08
AU2020360413A8 (en) 2022-04-21
CN119280227A (zh) 2025-01-10
EP4037678A4 (en) 2023-11-29
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2020013116A (es) Sales y cristales novedosos.
AR119158A1 (es) Tratamientos de angioedema hereditario
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
MX2017005299A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
IL307260A (en) Method for treating cancer
MX2019009841A (es) Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
NZ776354A (en) Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
AR090929A1 (es) Identificacion de la respuesta de un paciente a la administracion del modulador del receptor de s1p
ZA202000028B (en) Use of vibegron to treat overactive bladder
AR119159A1 (es) Tratamientos de angioedema
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
CA3156182A1 (en) METHODS FOR PROCESSING S1P1 RECEIVER BOUND STATES
AR080048A1 (es) Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib
RU2017126044A (ru) Соединение тиотриазола и его применения при лечении паразитарных протозойных инфекций
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.